glp-1 news nov 2025 ISPOR 2025: Exploring reasons for discontinuation Australian regulator warns of 'rare

As of 2026, retatrutide holds no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation and is classed as an unlicensed investigational peptide in the UK [1][6]

What people complain about: Slow titration is a major complaint

Proper retatrutide dosage is crucial for safe and informative research results

How Long Do GLP-1 Side Effects Last

And a few, particularly those related to Akkermansia muciniphila , raise legitimate safety questions that deserve serious attention, especially for people with autoimmune conditions, compromised immune systems, or inflammatory bowel disease

From actors to athletes, the world cant seem to get enough of this miracle drug. This insatiable appetite has ignited a heated debate surrounding safety and ethics